Intra-day variation of in vivo prostaglandin F2α formation in healthy subjects

被引:5
作者
Helmersson, Johanna [1 ]
Basu, Samar [1 ]
机构
[1] Uppsala Univ, Fac Med, Dept Publ Hlth & Caring Sci, SE-75185 Uppsala, Sweden
关键词
prostaglandin F-2 alpha; cyclooxygenase; human; daily variation;
D O I
10.1016/j.prostaglandins.2006.05.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prostaglandin F-2 alpha (PGF(2 alpha)) is a major stable prostaglandin formed in vivo in physiological and pathophysiological situations and has mainly potent vasoconstrictive and pro-inflammatory properties. PGF(2 alpha) is now used as an indicator of acute and chronic inflammation in human clinical settings but the extent of daily variation of PGF(2 alpha) in vivo in healthy humans is unknown. We quantified levels of the PGF, metabolite 15-keto-dihydro-PGF(2 alpha) in 10 healthy males and females in spot urine samples during the day (including morning urine sample) and in 24-h urine during the same day. The intra-day coefficient of variation was 20.9%. However, the total mean value of 15-keto-dihydro-PGF(2 alpha) in urine collected in the morning did not significantly differ from the mean level of 15-keto-dihydro-PGF(2 alpha) in the 24-h urine samples in the 10 subjects. 15-Keto-dihydro-PGF(2 alpha) levels in morning urine showed a positive linear correlation with levels of 15-keto-dihydro-PGF(2 alpha) in 24-h urine (R = 0.72, P < 0.05). In conclusion, formation of PGF(2 alpha) shows a biological variation within the day in healthy humans which should not be overlooked when planning a clinical study. Single morning urine samples can be used as an alternative to 24-h urine collections for quantification of PGF(2 alpha) formation to simplify the sampling regime in larger clinical studies. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:93 / 99
页数:7
相关论文
共 26 条
[1]  
Basu S, 2005, DIABETOLOGIA, V48, pA138
[2]   Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation [J].
Basu, S ;
Vessby, B ;
Larsson, A ;
Berne, C ;
Vessby, J .
DIABETES CARE, 2005, 28 (06) :1371-1375
[3]  
BASU S, 1987, ACTA VET SCAND, V28, P409
[4]   DEVELOPMENT OF A CONTINUOUS BLOOD COLLECTION TECHNIQUE AND A DETAILED STUDY OF PROSTAGLANDIN-F2-ALPHA RELEASE DURING LUTEOLYSIS AND EARLY-PREGNANCY IN HEIFERS [J].
BASU, S ;
KINDAHL, H .
JOURNAL OF VETERINARY MEDICINE SERIES A-PHYSIOLOGY PATHOLOGY CLINICAL MEDICINE, 1987, 34 (07) :487-500
[5]   Oxidative injury and survival during endotoxemia [J].
Basu, S ;
Eriksson, M .
FEBS LETTERS, 1998, 438 (03) :159-160
[6]   Radioimmunoassay of 15-keto-13,14-dihydro-prostaglandin F2α:: an index for inflammation via cyclooxygenase catalysed lipid peroxidation [J].
Basu, S .
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1998, 58 (05) :347-352
[7]   Lipid peroxidation induced by an early inflammatory response in endotoxaemia [J].
Basu, S ;
Eriksson, M .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2000, 44 (01) :17-23
[8]   Raised levels of F2-isoprostanes and prostaglandin F2α in different rheumatic diseases [J].
Basu, S ;
Whiteman, M ;
Mattey, DL ;
Halliwell, B .
ANNALS OF THE RHEUMATIC DISEASES, 2001, 60 (06) :627-631
[9]   PHOSPHOLIPID DEGRADATION AND CELLULAR EDEMA INDUCED BY FREE-RADICALS IN BRAIN CORTICAL SLICES [J].
CHAN, PH ;
YURKO, M ;
FISHMAN, RA .
JOURNAL OF NEUROCHEMISTRY, 1982, 38 (02) :525-531
[10]   MEASUREMENT OF 11-KETOTETRANOR PGF METABOLITES - AN APPROACH FOR MONITORING PROSTAGLANDIN-F2-ALPHA RELEASE IN THE MARE [J].
GOFF, AK ;
BASU, S ;
KINDAHL, H .
THERIOGENOLOGY, 1984, 21 (06) :887-896